TROG 97.01 - Bladder (Phase II) - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

13 November, 2024

Trek4TROG team rise to Blue Mountains challenge

November 2024: Congratulations to the Trek4TROG team for successfully

24 October, 2024

Promising new results from RAIDER trial published

24 October 2024: Newly published findings from the TROG

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

TROG 98.01 – Rectal (Phase II)

TROG 96.07 – Merkel Cell – Skin

Related Post

Trek4TROG team rise to Blue Mountains challenge

Promising new results from RAIDER trial published

Register for the 2025 ASM

TROG 97.01 – Bladder (Phase II)

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

TROG 98.01 – Rectal (Phase II)

TROG 96.07 – Merkel Cell – Skin

Related Post

Trek4TROG team rise to Blue Mountains challenge

Promising new results from RAIDER trial published

Register for the 2025 ASM